NCT05101915 (NOMAB) is a Phase 2 clinical trial of RESP301 in Cystic Fibrosis, sponsored by Papworth Hospital NHS Foundation Trust.

Who is sponsoring NCT05101915?

NCT05101915 is sponsored by Papworth Hospital NHS Foundation Trust.

What drugs are being tested in NCT05101915?

Interventions in NCT05101915: RESP301.

What condition does NCT05101915 study?

NCT05101915 studies Cystic Fibrosis.

Is NCT05101915 still recruiting?

NCT05101915 is currently terminated. Last updated 10 May 2024.

Last reviewed 2024-05-10 · How we verify

NCT05101915: NOMAB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus

Terminated Phase 2 Last updated 10 May 2024

What this trial tests

Phase 2 trial testing RESP301 in Cystic Fibrosis in 6 participants. Terminated before completion.

Timeline

1 November 2021

Primary endpoint
31 January 2024

23 April 2024

Quick facts

Lead sponsor	Papworth Hospital NHS Foundation Trust
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	1 November 2021
Primary completion	31 January 2024
Estimated completion	23 April 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

RESP301 — full drug profile →

Conditions studied

Cystic Fibrosis — all drugs for Cystic Fibrosis →

Sponsor

Papworth Hospital NHS Foundation Trust

Who can join

18 and older, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* To evaluate the change in M. abscessus cfu/g in induced sputum samples from baseline to the end of treatment with RESP301 in patients with cystic fibrosis who have treatment-naïve or treatment-refractory M. abscessus-pulmonary disease * To assess the safety and tolerability of RESP301 during treatment (28 days) and follow up (84 days) in patients with cystic fibrosis who have treatment naïve or treatment refractory M. abscessus-pulmonary disease

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

The Triple Crown: NO, CO, and H2S in cancer cell biology.
Oza PP, Kashfi K. · · 2023 · cited 45× · PMID 37517510 · DOI 10.1016/j.pharmthera.2023.108502
Advances in the Cystic Fibrosis Drug Development Pipeline.
Esposito C, Kamper M, Trentacoste J, Galvin S, et al · · 2023 · cited 10× · PMID 37763239 · DOI 10.3390/life13091835
Utility of NO and H2S donating platforms in managing COVID-19: Rationale and promise.
Oza PP, Kashfi K. · · 2022 · cited 6× · PMID 36029975 · DOI 10.1016/j.niox.2022.08.003
Clinical Trials involving Mycobacterium abscessus: An update.
Moore JE, Millar BC. · · 2025 · PMID 40313987

Verify or expand the search:

Other trials of RESP301

Trials testing the same drug.

NCT06041919 — Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis · Phase 2 · terminated
NCT04386070 — Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 · Phase 3 · suspended
NCT04858451 — COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2 · Phase 2 · terminated

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting

Other Papworth Hospital NHS Foundation Trust trials

Trials by the same sponsor.

NCT07289100 — Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchie · recruiting
NCT06433960 — Radial Artery Assessment in Surgical Coronary Revascularisation · completed
NCT05775263 — Validation of UK Protocols to Exclude Brain Blood Flow During Normothermic Regional Perfusion (NRP) · unknown
NCT06421792 — PrOtamIne doSing clOt imagiNg (POISON) Study · not yet recruiting
NCT06072872 — Portable Continuous Positive Airways Pressure (CPAP) in Excessive Central Airway Collapse (ECAC) Study · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05101915 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Papworth Hospital NHS Foundation Trust
Last refreshed: 10 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05101915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing